Welcome to our dedicated page for CRSWF news (Ticker: CRSWF), a resource for investors and traders seeking the latest updates and insights on CRSWF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CRSWF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CRSWF's position in the market.
Biomind Labs, a biotech company, announced the approval of its second Phase II clinical trial for N, N-dimethyltryptamine (DMT) targeting treatment-resistant depression, sanctioned by the Brazilian Institutional Review Board. This trial will explore an inhaled formulation of DMT, designed to provide quick yet effective therapeutic options. The study will involve 40 participants and aims to integrate fast-acting psychedelic treatments into existing psychiatric practices, enhancing treatment accessibility for diverse patient incomes.
Biomind Labs Inc. (OTC: CRSWF) announces positive results from in vivo studies on its BMND07 drug candidate, demonstrating low acute oral toxicity and no mutagenic effects across all dosages. This milestone aids in progressing the candidate towards Investigational New Drug studies, where new data will help in selecting appropriate dose levels and establishing safety protocols for human exposure. The company focuses on developing affordable treatments utilizing DMT, 5-MeO-DMT, and mescaline to address mental health disorders.
Biomind Labs Inc. (OTC: CRSWF) has announced its common shares are now eligible for electronic clearing and settlement through the Depository Trust Company (DTC) in the U.S. This development follows their recent listing on the OTCQB Venture Market on February 17, 2022. CEO Alejandro Antalich emphasized that DTC eligibility will enhance trading accessibility for U.S. investors, potentially increasing liquidity and visibility, and attracting greater investment. Biomind Labs focuses on research and development of psychedelic treatments for mental health disorders.
Biomind Labs Inc. has successfully upgraded from OTC Pink to the OTCQB Venture Market, starting trading under the symbol CRSWF. This advancement enhances the company's visibility, liquidity, and shareholder base in the U.S. market. CEO Alejandro Antalich noted that this milestone aligns with their goal of submitting Investigational New Drug applications to the FDA. The OTCQB platform is recognized by the SEC and offers investors comprehensive public information for trading.
